ArticleNews reportPHN-05152026-10-31 13:37 CT

Peptide-Linked Death Casts Shadow Over RFK Jr.'s Push for Expanded Access—FDA Review Continues

Source · TrialSite News

TLDR

TrialSite News reports that a coroner linked Richard Norton's death at 75 to experimental CJC-1295 and ipamorelin injections, with anaphylaxis implicated. Separately, the article reports that HHS announced a conditional enforcement-discretion policy for six peptides while FDA review continues; the action does not grant FDA approval.

01—Key points

01According to the article, the coroner identified clinical oversight shortcomings and recommended reconsidering Australian restrictions.
02The reported HHS policy covers qualifying licensed compounders; none of the six peptides was added to the FDA Bulks List.
03The article reports FDA reviewers raised concerns about insufficient human evidence, manufacturing uncertainties and potential safety risks.

Why it matters Editorial

The report highlights the distinction between conditional access to compounded peptides and evidence establishing their safety and efficacy.

Read the original at TrialSite News↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.